Debut, a San Diego, CA-based vertically integrated synthetic biology company focused on beauty, raised $40M in Series B funding.
The round was led by Bold.
The company intends to use the funds to accelerate the development of bio-identical and novel fragrance molecules.
Led by Founder and CEO Joshua Britton, Ph.D, Debut is an innovation company whose vertically integrated synthetic biology platform unlocks a new generation of cosmetic bioactive ingredients using advanced biomanufacturing approaches. Its advanced biomanufacturing will enable fragrance brands to transition to bio-based formulas, while protecting the olfactive integrity of their formulas. Debut’s biotechnology can replicate the scent signature and precise characteristics of natural ingredients, including those that are structurally complex, difficult to source, and only exist in trace amounts in nature. The company will also develop novel fragrance molecules, opening new creative possibilities for the fragrance industry.
FinSMEs
19/10/2023